eBay Inc vs Novo Nordisk A/S — how do they compare? eBay Inc trades at $106.12 (market cap $47.17B), while Novo Nordisk A/S trades at $45.89 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 4.4× eBay Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| EBAY | NVO | |
|---|---|---|
Market Cap | $47.17B | $207.85B |
Volume | 5,186,418 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $118.96 | $63.98 |
52-Week Low | $79.41 | $35.29 |
Enterprise Value | $51.00B | $222.55B |
Dividend Yield | 1.17% | 3.81% |
Signals from Pluang's Aura AI — not financial advice
EBAY trades at $107.71, down 3.81% on news that GameStop may abandon its $56 billion takeover bid in favor of a partnership. The stock shows bearish technical signals but maintains strong fundamentals with 18.57% net margins and consistent earnings beats. Recent Q2 results exceeded expectations with 14% GMV growth, though insider selling and takeover uncertainty create near-term pressure.
EBAY offers solid fundamentals with improving revenue guidance and attractive valuation multiples, but faces significant event risk from the potential GameStop deal collapse. The 11% upside to consensus price target suggests moderate bullish sentiment, though investors should monitor partnership developments and Q3 earnings for directional clarity.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →